Dr. Clay Siegall is the CEO and president of Seattle Genetics, a business he founded 20 years ago. He is also a sports enthusiast who likes to blog about sports and science. He recently posted an ESPN article, for example, that talks about the Philadelphia Eagles and how 9 of their player acquisitions over the span of a week was key to them getting into the Super Bowl. The article describes how each point that they scored during the rout of the Minnesota Vikings during the conference championship was achieved by a player who hadn’t even been on the roster the year prior.
Another ESPN article he posted is about the other Super Bowl contender, the New England Patriots. The article describes how their quarterback Tom Brady cut a weekly interview he does short. The reason for this is that one of the radio station’s hosts had called his five-year-old daughter “an annoying little pissant”. The comment was made by Kirk Minihane who makes appearances from time to time on the “Kirk & Callahan Show”.
Dr. Clay Siegall has been in the biotechnology industry for over 30 years. His specialty is creating targeted cancer drug therapies from anti-body drug conjugates. He says that it’s his passion to create targeted cancer drug therapies for a number of reasons. First, they’re much more effective than the older, conventional methods such as the use of radiation and chemotherapy. Second, they are much better tolerated by the body as the only kill cells with cancer, not those that are healthy.
Since 2006, Dr. Clay Siegall has also joined the board of directors for other firms in the industry. There are three companies he is on the board for including Alder Biopharmaceuticals, Inc., Ultragenyx Pharmaceutical, and Mirna Therapeutics, Inc. He was chosen to be one these boards because of his deep experience in the biotechnology industry as well as his proven leadership skills.
At the University of Maryland he earned his undergraduate in zoology. His genetics doctorate of philosophy was earned at The George Washington University in 1988.